| Code | CSB-RA015057MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Trevogrumab, targeting myostatin (MSTN), a negative regulator of skeletal muscle growth and development. Myostatin, a member of the transforming growth factor-beta superfamily, functions by binding to activin type II receptors and inhibiting muscle fiber growth and differentiation. Elevated myostatin levels are associated with muscle wasting conditions including sarcopenia, cachexia, and muscular dystrophies, while genetic myostatin deficiency results in significant muscle hypertrophy in both animals and humans.
Trevogrumab is a fully humanized IgG2 monoclonal antibody that neutralizes myostatin activity by preventing its interaction with cell surface receptors. This biosimilar provides researchers with a valuable tool for investigating myostatin biology, muscle regeneration pathways, and metabolic regulation. It supports studies examining therapeutic strategies for muscle-wasting disorders, age-related muscle loss, and metabolic diseases where muscle mass plays a critical role. The antibody enables exploration of myostatin blockade mechanisms and downstream signaling pathways in various experimental models.
There are currently no reviews for this product.